Monopar Therapeutics (MNPR) Gains from Sales and Divestitures (2020 - 2025)
Monopar Therapeutics' (MNPR) quarterly Gains from Sales and Divestitures came in at $59847.0 in Q4 2025, up 76.06% year-on-year from $33992.0 in Q4 2024, and up 28.95% quarter-over-quarter from $46412.0 in Q3 2025.
Monopar Therapeutics (MNPR) Gains from Sales and Divestitures (2020 - 2025) Analysis & Trends
Monopar Therapeutics has disclosed Gains from Sales and Divestitures across 6 years of filings, most recently posting $59847.0 for Q4 2025.
- Gains from Sales and Divestitures for Q4 2025 came in at $59847.0, up 76.06% year-over-year; the trailing twelve-month figure through Dec 2025 was $59847.0 (up 76.06% YoY), and the FY2025 annual result was $59847.0, up 76.06% from the prior year.
- Gains from Sales and Divestitures came in at $59847.0 for Q4 2025 at Monopar Therapeutics, up from $46412.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $169167.0 in Q3 2023 to a low of $12316.0 in Q1 2025.
- The 5-year median for Gains from Sales and Divestitures is $46412.0 (2025), against an average of $64542.8.
- Across the five-year window, Gains from Sales and Divestitures jumped 865.05% in 2021 and tumbled 84.11% in 2024, its largest moves.
- Monopar Therapeutics' Gains from Sales and Divestitures stood at $49758.0 in 2021, then surged by 200.87% to $149706.0 in 2022, then slumped by 70.22% to $44585.0 in 2023, then fell by 23.76% to $33992.0 in 2024, then soared by 76.06% to $59847.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $59847.0 (Q4 2025), $46412.0 (Q3 2025), and $32975.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Monopar Therapeutics | 445.85 Mn | 445.85 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 59,847.00 |
| Dec 31, 2025 | 59,847.00 |
| Sep 30, 2025 | 46,412.00 |
| Sep 30, 2025 | 46,412.00 |
| Jun 30, 2025 | 32,975.00 |
| Jun 30, 2025 | 32,975.00 |
| Mar 31, 2025 | 12,316.00 |
| Mar 31, 2025 | 12,316.00 |
| Dec 31, 2024 | 33,992.00 |
| Dec 31, 2024 | 33,992.00 |
| Sep 30, 2024 | 26,888.00 |
| Sep 30, 2024 | 26,888.00 |
| Jun 30, 2024 | 98,910.00 |
| Jun 30, 2024 | 98,910.00 |
| Mar 31, 2024 | 51,557.00 |
| Mar 31, 2024 | 51,557.00 |
| Dec 31, 2023 | 44,585.00 |
| Dec 31, 2023 | 44,585.00 |
| Sep 30, 2023 | 169,167.00 |
| Sep 30, 2023 | 169,167.00 |